Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Radioprotection Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LPAR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Overexpression | LPAR2 Full-Length Lentivirus Particles For stable cell line construction preserving native 7-transmembrane conformation. |
View LPAR2 Products |
| Gene Delivery | LPAR2 Promise-ORF / Lentivirus Full-length ORF sequence-verified for expression validation. |
View LPAR2 Products |
| Benchmark Ab | Anti-LPAR2 Recombinant Antibody Sequence-verified positive control for flow cytometry and binding assays. |
View LPAR2 Products |
| Validator | LPAR2 siRNA Set Target-specific knockdown verification in functional assays. |
View LPAR2 Products |
| Related Target A | LPAR1 Critical subfamily member for selectivity and off-target safety screening. |
View LPAR1 Products |
| Related Target B | LPAR3 Homologous GPCR required for cross-reactivity profiling in LPA receptor drug discovery. |
View LPAR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent GPCR binding | Lentivirus-driven stable cell lines ensure native 7-TM folding (No VLPs recommended). |
| Subfamily off-target screening | Sequence-verified LPAR1 and LPAR3 reference reagents available for counter-screening. |
| Lack of Controls | Recombinant benchmark antibodies included for assay standardization. |
| False Positives | Sequence-specific siRNA pool included for target-knockdown validation. |
Live LPAR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LPAR2 therapeutics is intensifying, with major players shifting focus from traditional small molecules to highly selective biologics and targeted GPCR modulators. As first-generation radioprotective agonists and oncological antagonists reach clinical validation, the next wave of R&D is targeting precise subfamily selectivity to avoid off-target cardiovascular and pulmonary side effects associated with LPAR1 and LPAR3 activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | RxBio, Academic Institutions | Colorectal Cancer, Fibrosis | Selectivity Assay (Need LPAR1/3/2 comparative cell lines) |
| Monoclonal Antibodies / Nanobodies | Biotech Innovators | Ovarian Cancer, Metastasis | Native Conformation Binding (Need Lentivirus-expressed cell lines) |
| Agonists (Radioprotectants) | Neumedicines, RxBio | Acute Radiation Syndrome | Functional Signaling Assay (Need high-titer Lentivirus for reporter assays) |